Overview Dividends

(DXCM) DexCom - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074

Continuous Glucose Monitoring Systems, Glucose Biosensors, Remote Monitoring

DXCM EPS (Earnings per Share)

EPS Growth (3Y CAGR): 21.65%
EPS Trend (3Y Correlation): 47.1%

DXCM Revenue

Revenue Growth (3Y CAGR): 15.99%
Revenue Trend (3Y Correlation): 89.8%

Description: DXCM DexCom

DexCom Inc (NASDAQ:DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management. The companys product portfolio includes Dexcom G6 and G7, integrated CGM systems, as well as remote monitoring and data integration solutions like Dexcom Share and Dexcom Real-Time API.

The companys focus on CGM technology has enabled it to establish a strong presence in the diabetes management market, with products designed for patients, caregivers, and clinicians. Additionally, Dexcom has expanded its offerings to include Stelo, a glucose biosensor for adults with prediabetes and Type 2 diabetes, available over-the-counter.

From a financial perspective, DXCM has demonstrated strong growth, with a Return on Equity (RoE) of 24.38%. The companys market capitalization stands at approximately $32.5 billion, indicating a significant presence in the healthcare equipment sector. Key Performance Indicators (KPIs) such as revenue growth rate, gross margin, and operating margin would provide further insights into the companys financial health and operational efficiency.

To further evaluate DXCMs potential, we can examine its competitive positioning, market share, and product pipeline. The companys collaboration with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products is a notable strategic move. Analyzing KPIs such as customer acquisition cost, customer retention rate, and research and development (R&D) expenditure as a percentage of revenue can help assess the companys ability to innovate and maintain its market position.

DXCM Stock Overview

Market Cap in USD	31,670m
Sub-Industry	Health Care Equipment
IPO / Inception	2005-04-14

DXCM Stock Ratings

Growth Rating	3.37%
Fundamental	75.4%
Dividend Rating	-
Return 12m vs S&P 500	-6.45%
Analyst Rating	4.54 of 5

DXCM Dividends

Currently no dividends paid

DXCM Growth Ratios

Growth Correlation 3m	-68.8%
Growth Correlation 12m	38.4%
Growth Correlation 5y	-29.7%
CAGR 5y	-3.30%
CAGR/Max DD 3y	-0.06
CAGR/Mean DD 3y	-0.17
Sharpe Ratio 12m	-0.10
Alpha	0.01
Beta	0.915
Volatility	42.39%
Current Volume	7419.5k
Average Volume 20d	4300.5k
Stop Loss	73.6 (-3.7%)
Signal	0.05

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (571.5m TTM) > 0 and > 6% of Revenue (6% = 258.0m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA -2.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 40.03% (prev 79.45%; Δ -39.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 987.7m > Net Income 571.5m (YES >=105%, WARN >=100%)

Net Debt (1.42b) to EBITDA (1.04b) ratio: 1.37 <= 3.0 (WARN <= 3.5)

Current Ratio 1.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (408.2m) change vs 12m ago -2.06% (target <= -2.0% for YES)

Gross Margin 58.77% (prev 62.74%; Δ -3.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 60.89% (prev 57.87%; Δ 3.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 42.27 (EBITDA TTM 1.04b / Interest Expense TTM 19.0m) >= 6 (WARN >= 3)

Altman Z'' 3.58

(A) 0.23 = (Total Current Assets 5.03b - Total Current Liabilities 3.31b) / Total Assets 7.33b

(B) 0.26 = Retained Earnings (Balance) 1.88b / Total Assets 7.33b

(D) 0.41 = Book Value of Equity 1.97b / Total Liabilities 4.75b

Total Rating: 3.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.35

1. Piotroski 7.0pt = 2.0

2. FCF Yield 1.83% = 0.91

3. FCF Margin 13.27% = 3.32

4. Debt/Equity 0.96 = 2.06

5. Debt/Ebitda 2.38 = -0.73

6. ROIC - WACC (= 5.25)% = 6.56

7. RoE 25.62% = 2.14

8. Rev. Trend 89.85% = 6.74

9. EPS Trend 47.15% = 2.36

What is the price of DXCM shares?

As of September 18, 2025, the stock is trading at USD 76.44 with a total of 7,419,501 shares traded.
Over the past week, the price has changed by +0.58%, over one month by -5.42%, over three months by -6.59% and over the past year by +10.88%.

Is DexCom a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, DexCom (NASDAQ:DXCM) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.35 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DXCM is around 68.47 USD . This means that DXCM is currently overvalued and has a potential downside of -10.43%.

Is DXCM a buy, sell or hold?

DexCom has received a consensus analysts rating of 4.54. Therefore, it is recommended to buy DXCM.

Strong Buy: 17
Buy: 6
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DXCM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	102.1	33.5%
Analysts Target Price	102.1	33.5%
ValueRay Target Price	76.5	0.1%

Last update: 2025-09-05 04:40

DXCM Fundamental Data Overview

Market Cap USD = 31.67b (31.67b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 2.93b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 56.8732
P/E Forward = 30.2115
P/S = 7.3638
P/B = 12.0279
P/EG = 0.9979
Beta = 1.487
Revenue TTM = 4.30b USD
EBIT TTM = 803.1m USD
EBITDA TTM = 1.04b USD
Long Term Debt = 1.24b USD (from longTermDebt, last quarter)
Short Term Debt = 1.23b USD (from shortTermDebt, last quarter)
Debt = 2.47b USD (Calculated: Short Term 1.23b + Long Term 1.24b)
Net Debt = 1.42b USD (from netDebt column, last quarter)
Enterprise Value = 31.21b USD (31.67b + Debt 2.47b - CCE 2.93b)
Interest Coverage Ratio = 42.27 (Ebit TTM 803.1m / Interest Expense TTM 19.0m)
FCF Yield = 1.83% (FCF TTM 570.8m / Enterprise Value 31.21b)
FCF Margin = 13.27% (FCF TTM 570.8m / Revenue TTM 4.30b)
Net Margin = 13.29% (Net Income TTM 571.5m / Revenue TTM 4.30b)
Gross Margin = 58.77% ((Revenue TTM 4.30b - Cost of Revenue TTM 1.77b) / Revenue TTM)
Tobins Q-Ratio = 15.87 (Enterprise Value 31.21b / Book Value Of Equity 1.97b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.47b)
Taxrate = 18.73% (132.8m / 709.0m)
NOPAT = 652.7m (EBIT 803.1m * (1 - 18.73%))
Current Ratio = 1.52 (Total Current Assets 5.03b / Total Current Liabilities 3.31b)
Debt / Equity = 0.96 (Debt 2.47b / last Quarter total Stockholder Equity 2.57b)
Debt / EBITDA = 2.38 (Net Debt 1.42b / EBITDA 1.04b)
Debt / FCF = 4.32 (Debt 2.47b / FCF TTM 570.8m)
Total Stockholder Equity = 2.23b (last 4 quarters mean)
RoA = 7.80% (Net Income 571.5m, Total Assets 7.33b )
RoE = 25.62% (Net Income TTM 571.5m / Total Stockholder Equity 2.23b)
RoCE = 23.15% (Ebit 803.1m / (Equity 2.23b + L.T.Debt 1.24b))
RoIC = 13.97% (NOPAT 652.7m / Invested Capital 4.67b)
WACC = 8.72% (E(31.67b)/V(34.14b) * Re(9.39%)) + (D(2.47b)/V(34.14b) * Rd(0.19%) * (1-Tc(0.19)))
Shares Correlation 3-Years: -60.61 | Cagr: -0.38%
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.19% ; FCFE base≈608.7m ; Y1≈750.9m ; Y5≈1.28b
Fair Price DCF = 43.55 (DCF Value 17.08b / Shares Outstanding 392.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 47.15 | EPS CAGR: 21.65% | SUE: 0.51 | # QB: 0
Revenue Correlation: 89.85 | Revenue CAGR: 15.99% | SUE: N/A | # QB: None

Additional Sources for DXCM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle